[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 184.73.122.162. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 686
Citations 0
Clinical Trials Update
November 26, 2014

Evolocumab Lowers LDL in Genetic High Cholesterol Disorder

JAMA. 2014;312(20):2083. doi:10.1001/jama.2014.15519

Evolocumab (AMG145), inhibitor of an enzyme (PCSK9) that facilitates degradation of low-density lipoprotein (LDL) receptors, led to 60% greater reduction in LDL cholesterol than placebo in 331 patients with heterozygous familial hypercholesterolemia, reported a manufacturer-funded multicenter randomized trial (Raal FJ et al. Lancet. doi:10.1016/S0140-6736(14)61399-4 [published online October 2, 2014]).

Familial hypercholesterolemia is thought to be the most common disorder inherited in autosomal-dominant fashion, affecting between 1 in 250 to 300 people worldwide and more than 3 million people in the United States and Europe. Intensive statin therapy often fails to reduce LDL cholesterol to levels sufficient to prevent premature cardiovascular disease for people with the disorder.

First Page Preview View Large
First page PDF preview
First page PDF preview
×